The Mount Sinai Tisch Cancer Center (TCC) in the US has introduced an AI clinical trial matching platform, PRISM, to improve access to cancer research opportunities across its entire health system.
Developed by Triomics and powered by the OncoLLM large language model tailored for oncology, this deployment positions Mount Sinai as the first National Cancer Institute-designated Comprehensive Cancer Center in New York City to implement the platform systemwide for trial matching.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The adoption of PRISM aims to expand access to advanced cancer trials, expedite clinical trial enrolment, and ensure patients are considered for advanced treatment options earlier in their care journey.
The process involves analysing electronic health records (EHR), medical histories, diagnoses, and clinical characteristics to determine trial eligibility.
Traditionally, this required manual reviews of complex protocols and fragmented records, a time-consuming task that could delay or restrict patient access to new therapies.
This systemwide implementation ensures that individuals at Mount Sinai Brooklyn, Mount Sinai Morningside, Mount Sinai Queens, Mount Sinai South Nassau, Mount Sinai West, and additional sites have the same opportunities to participate in clinical trials as patients at The Mount Sinai Hospital.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMount Sinai plans ongoing evaluation of outcomes from PRISM’s deployment and will share results in future peer-reviewed publications and national scientific meetings.
Mount Sinai TCC’s clinical research associate director Karyn Goodman said: “Clinical trials are essential to advancing cancer care, but too often patients and their treating physicians are not aware of studies that may be appropriate for them.
“By deploying an AI platform trained specifically for oncology, we can identify trial opportunities earlier, more consistently, and more equitably, allowing clinicians to focus on meaningful conversations with patients rather than manual chart review.”
In August 2025, 60 Degrees Pharmaceuticals entered a clinical study agreement with the Icahn School of Medicine at Mount Sinai, selecting it as the site to conduct an open-label Phase II trial of Arakoda (tafenoquine) to treat chronic babesiosis.
